Ultragenyx Pharmaceutical Inc.RAREEarnings & Financial Report
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
RARE Q4 FY2025 Key Financial Metrics
Revenue
$207.3M
Gross Profit
N/A
Operating Profit
$-113.3M
Net Profit
$-128.6M
Gross Margin
N/A
Operating Margin
-54.7%
Net Margin
-62.0%
YoY Growth
25.9%
EPS
$-1.28
Ultragenyx Pharmaceutical Inc. Q4 FY2025 Financial Summary
Ultragenyx Pharmaceutical Inc. reported revenue of $207.3M (up 25.9% YoY) for Q4 FY2025, with a net profit of $-128.6M (up 3.5% YoY) (-62.0% margin).
Key Financial Metrics
| Total Revenue | $207.3M |
|---|---|
| Net Profit | $-128.6M |
| Gross Margin | N/A |
| Operating Margin | -54.7% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Ultragenyx Pharmaceutical Inc. Q4 FY2025 revenue of $207.3M breaks down across 2 segments, led by Royalty at $105.6M (50.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Royalty | $105.6M | 50.9% |
| Products | $101.7M | 49.1% |
Ultragenyx Pharmaceutical Inc. Revenue by Segment — Quarterly Trend
Ultragenyx Pharmaceutical Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Royalty and Products) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Royalty | $105.6M | $64.9M | $85.7M | — |
| Products | $101.7M | $95.0M | $80.8M | $91.5M |
Ultragenyx Pharmaceutical Inc. Annual Revenue by Year
Ultragenyx Pharmaceutical Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $673.0M).
Ultragenyx Pharmaceutical Inc. Quarterly Revenue & Net Profit History
Ultragenyx Pharmaceutical Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $207.3M | +25.9% | $-128.6M | -62.0% |
| Q3 FY2025 | $159.9M | +14.7% | $-180.4M | -112.8% |
| Q2 FY2025 | $166.5M | +13.2% | $-115.0M | -69.0% |
| Q1 FY2025 | $139.3M | +28.0% | $-151.1M | -108.5% |
| Q4 FY2024 | $164.6M | +29.5% | $-133.2M | -80.9% |
| Q3 FY2024 | $139.5M | +42.3% | $-133.5M | -95.7% |
| Q2 FY2024 | $147.0M | +35.7% | $-131.6M | -89.5% |
| Q1 FY2024 | $108.8M | +8.3% | $-170.7M | -156.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $108.8M | $147.0M | $139.5M | $164.6M | $139.3M | $166.5M | $159.9M | $207.3M |
| YoY Growth | 8.3% | 35.7% | 42.3% | 29.5% | 28.0% | 13.2% | 14.7% | 25.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.31B | $1.62B | $1.54B | $1.50B | $1.31B | $1.31B | $1.19B | $1.53B |
| Liabilities | $1.17B | $1.19B | $1.18B | $1.24B | $1.16B | $1.15B | $1.17B | $1.60B |
| Equity | $140.3M | $432.4M | $346.8M | $255.0M | $144.2M | $151.3M | $9.2M | $-80.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-190.7M | $-77.0M | $-67.0M | $-79.3M | $-166.5M | $-108.3M | $-91.4M | $-99.8M |